Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal , Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A
PURPOSE: Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored.
MATERIALS AND METHODS: Safety data were collected...